Item Type | Name |
Concept
|
Immunotherapy
|
Concept
|
Immunotherapy, Adoptive
|
Concept
|
Immunotherapy, Active
|
Academic Article
|
Rational development of tumour antigen-specific immunization in melanoma.
|
Academic Article
|
Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells.
|
Academic Article
|
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
|
Academic Article
|
Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines.
|
Academic Article
|
Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites.
|
Academic Article
|
The p815 mastocytoma tumor model.
|
Academic Article
|
Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma.
|
Academic Article
|
Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.
|
Academic Article
|
Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.
|
Academic Article
|
Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy.
|
Academic Article
|
Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy.
|
Academic Article
|
Emerging strategies in regulatory T-cell immunotherapies.
|
Academic Article
|
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".
|
Academic Article
|
Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011.
|
Academic Article
|
Harnessing the immune response.
|
Academic Article
|
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
|
Academic Article
|
Defining the critical hurdles in cancer immunotherapy.
|
Academic Article
|
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery.
|
Academic Article
|
Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation.
|
Academic Article
|
Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics.
|
Academic Article
|
Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma.
|
Academic Article
|
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.
|
Academic Article
|
Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer.
|
Academic Article
|
Cancer immunotherapy.
|
Academic Article
|
Cancer immunotherapy.
|
Academic Article
|
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment.
|
Academic Article
|
Targeting the tumor microenvironment with interferon-ß bridges innate and adaptive immune responses.
|
Academic Article
|
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.
|
Academic Article
|
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
|
Academic Article
|
Innate immune recognition of cancer.
|
Academic Article
|
Melanoma-intrinsic ß-catenin signalling prevents anti-tumour immunity.
|
Academic Article
|
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
|
Academic Article
|
Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.
|
Academic Article
|
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
|
Academic Article
|
Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy.
|
Academic Article
|
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
|
Academic Article
|
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
|
Academic Article
|
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.
|
Academic Article
|
Manipulating the microbiome to improve the efficacy of immunotherapy.
|
Academic Article
|
Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy.
|
Academic Article
|
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.
|
Academic Article
|
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
|
Academic Article
|
Innate immune signaling and regulation in cancer immunotherapy.
|
Academic Article
|
Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.
|
Academic Article
|
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
|
Academic Article
|
Impact of oncogenic pathways on evasion of antitumour immune responses.
|
Academic Article
|
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy).
|
Academic Article
|
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
|
Academic Article
|
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies.
|
Academic Article
|
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
|
Academic Article
|
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
|
Academic Article
|
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.
|
Academic Article
|
Fast Forward - Neoadjuvant Cancer Immunotherapy.
|
Academic Article
|
Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.
|
Academic Article
|
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
|
Academic Article
|
Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
|
Academic Article
|
Brain Tumor Microenvironment and Host State: Implications for Immunotherapy.
|
Academic Article
|
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy).
|
Academic Article
|
Secondary resistance to immunotherapy associated with ß-catenin pathway activation or PTEN loss in metastatic melanoma.
|
Academic Article
|
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.
|
Academic Article
|
Exploring the emerging role of the microbiome in cancer immunotherapy.
|
Academic Article
|
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.
|
Academic Article
|
cDC1 dysregulation in cancer: An opportunity for intervention.
|
Academic Article
|
Immunotherapy with a sting.
|
Academic Article
|
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy).
|
Academic Article
|
Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy.
|
Academic Article
|
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy).
|
Academic Article
|
Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma.
|
Academic Article
|
Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma.
|
Academic Article
|
Microbiome-based interventions: therapeutic strategies in cancer immunotherapy.
|
Academic Article
|
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
|
Academic Article
|
Tissue-resident memory T cells in immune-related adverse events: friend or foe?
|
Academic Article
|
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
|
Academic Article
|
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy.
|